{"product_id":"fulgentgenetics-five-forces-analysis","title":"Fulgent Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFulgent faces intense rivalry from well-capitalized diagnostics firms, moderate supplier leverage for specialized reagents, and rising substitute pressures from point-of-care testing and telehealth innovations; buyer power is growing as payors push for cost-efficiency, while regulatory barriers limit but do not eliminate new entrants.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Fulgent’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Sequencing Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe next-generation sequencing (NGS) hardware market is highly concentrated—Illumina held roughly 80% global market share in 2024—creating strong supplier power over Fulgent and similar labs.\u003c\/p\u003e\n\u003cp\u003eThese suppliers set prices for core reagents and service contracts; reagent spend can account for 30–40% of per-test COGS, directly squeezing margins.\u003c\/p\u003e\n\u003cp\u003eSwitching costs are high: platform revalidation, software integration, and staff retraining can take 6–12 months and cost millions, so suppliers keep substantial leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Reagent Availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent depends on high-purity reagents and proprietary biologicals for genetic tests; in 2024 reagent spend rose ~12% as volume grew, making supply stability critical. Disruptions or price hikes from niche suppliers can cut lab EBIT margins, which were 14.8% in FY2024 for comparable labs, by several percentage points. Limited alternative sources give suppliers moderate-to-high bargaining power, especially for proprietary enzymes and single-source kits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Cloud Infrastructure and Bioinformatics Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent depends on high-performance cloud providers and niche bioinformatics vendors to process terabytes per run from next-gen sequencing; in 2024 the global genomics cloud spend surpassed $2.4B, concentrating bargaining power among major providers.\u003c\/p\u003e\n\u003cp\u003eThese partners power proprietary algorithms that drive Fulgent’s diagnostic accuracy and revenue—bioinformatics licenses and cloud costs can represent 8–12% of lab operating expenses.\u003c\/p\u003e\n\u003cp\u003eMultiple cloud options exist, but deep workflow integration makes migration costly—estimates show replatforming pipelines can take 6–12 months and cost $3–8M—giving suppliers notable influence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition for Highly Skilled Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe pool of specialized geneticists, bioinformaticians, and molecular lab technicians is tight vs. booming biotech demand; US Bureau of Labor Statistics data show bioinformatics jobs grew ~19% 2020–2023 and median biotech lab pay rose to ~$95,000 in 2023, letting talent demand premium pay.\u003c\/p\u003e\n\u003cp\u003eThose workers act as powerful labor suppliers, extracting higher salaries, signing bonuses, and equity, forcing Fulgent to raise compensation.\u003c\/p\u003e\n\u003cp\u003eFulgent must keep investing in pay, training, and remote\/hybrid flexibility to avoid losses to Big Pharma and top universities; a 2024 industry survey found 42% of genomic researchers considered switching employers that year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabor scarcity → higher pay (median ~$95k, bioinformatics +19% growth)\u003c\/li\u003e\n\u003cli\u003eTalent behaves like supplier → greater bargaining power\u003c\/li\u003e\n\u003cli\u003eFulgent needs pay, training, flexibility to retain staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold-Chain Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe integrity of genetic samples depends on a few specialized cold‑chain logistics firms that can hold -20°C to -80°C; in 2024 the global cold chain market hit $281B and medical cold-chain growth was ~10% CAGR, narrowing Fulgent’s partner set.\u003c\/p\u003e\n\u003cp\u003eThese providers can raise fuel surcharges and service fees; in 2023 air freight fuel surcharges rose 15–30%, and switching carriers risks sample loss or regulatory noncompliance, giving suppliers tangible leverage over margins.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eFew qualified partners: high technical and regulatory bar\u003c\/li\u003e\n\u003cli\u003eMedical cold-chain market: $281B (2024), ~10% CAGR\u003c\/li\u003e\n\u003cli\u003eFuel surcharges rose 15–30% in 2023\u003c\/li\u003e\n\u003cli\u003eSwitching risk: sample degradation, compliance failures\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina dominance, costly reagents \u0026amp; cloud\/bioinformatics lock in suppliers’ power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert moderate-to-high power: Illumina’s ~80% NGS share (2024) and proprietary reagents (30–40% of COGS) raise prices; cloud\/bioinformatics and cold‑chain concentration ($2.4B genomics cloud spend, $281B cold chain 2024) plus tight talent (median ~$95k, bioinformatics +19% 2020–23) make switching costly (6–12 months, $3–8M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina NGS share\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent % of COGS\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics cloud spend\u003c\/td\u003e\n\u003ctd\u003e$2.4B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain market\u003c\/td\u003e\n\u003ctd\u003e$281B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioinformatics pay\u003c\/td\u003e\n\u003ctd\u003emedian ~$95k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Fulgent: concise evaluation of competitive rivalry, buyer and supplier power, substitution threats, and entry barriers, highlighting disruptive risks and strategic levers to defend market share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-pager for Fulgent—instantly highlights competitive pressures and strategic levers so decision-makers can prioritize actions and reduce analysis time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Major Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge payers us insurers and medicare pricing for genetic tests often setting fixed reimbursements that squeeze margins clinical lab fee schedule cut rates some molecular by up to in pressuring labs.\u003e\n\u003cpif a major insurer trims coverage or pays less for fulgent assay the lab risks losing big-volume contracts insurers account roughly of revenue in comparable peers so negotiating leverage is minimal.\u003e\n\u003c\/pif\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Hospital Systems and Clinician Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpas hospital systems consolidated mergers rose from leaving the top responsible for of discharges gained price power and can demand volume discounts diagnostics. these large institutional buyers leverage scale to secure lower per-test pricing via exclusive or preferred-provider contracts pressuring fulgent margins. must now compete on turnaround time integrated it services win multi-year deals with major medical centers. in median lab contract savings ranged forcing tighter negotiations.\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Market Price Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn elective and wellness genetic testing, consumers are highly price-sensitive since most tests lack insurance coverage; surveys in 2024 showed 68% of buyers compare prices across 3+ platforms before purchase. This transparency and over 100 US consumer genetic-testing offerings in 2025 cap Fulgent Genetics’ pricing power, so a 10% price increase would likely cut volume by an estimated 6–12% based on industry elasticities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinicians can reroute samples easily; 2024 CMS data show referral labs compete on turnaround and price, so switching from Fulgent is low-cost and fast.\u003c\/p\u003e\n\u003cp\u003eMost labs offer similar digital reports and shipping; this gives physicians leverage to demand higher-quality, broader panels and faster TATs—pressuring Fulgent on margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow physical switching cost: samples shippable nationwide\u003c\/li\u003e\n\u003cli\u003eDigital parity: comparable reporting UIs across labs\u003c\/li\u003e\n\u003cli\u003eBuyer leverage: demand for quality, breadth, speed\u003c\/li\u003e\n\u003cli\u003eMarket signal: reference lab price pressure in 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformation Transparency and Comparative Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInformation transparency—driven by third-party reviews, peer-reviewed clinical validity studies, and pricing tools—lets institutional buyers and patients compare Fulgent’s sensitivity and specificity versus competitors; recent 2024 meta-analyses show top labs’ PCR sensitivity clustering 95–99%, so small percentage gaps are easy to spot.\u003c\/p\u003e\n\u003cp\u003eThis visibility cuts information asymmetry that once favored labs, shifting bargaining power to buyers who now demand lower prices, faster turnaround, and published accuracy; Fulgent’s FY2024 revenue mix (≈40% COVID-era tests) raises buyer leverage when service mixes change.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party reviews increase buyer knowledge\u003c\/li\u003e\n\u003cli\u003eClinical studies expose small accuracy differences (95–99%)\u003c\/li\u003e\n\u003cli\u003ePricing tools enable direct cost comparisons\u003c\/li\u003e\n\u003cli\u003eFY2024 mix shift (~40% COVID tests) heightens buyer leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Tighten Screws: Payers, Hospitals \u0026amp; Consumers Drive Prices Down, Speed Up Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbuyers hold strong leverage: insurers set reimbursements cuts up to for some molecular tests in drive of lab revenue hospital system consolidation discharges yields volume discounts consumer price-shopping compare platforms and transparent accuracy sensitivity force lower prices faster tats.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare cuts\u003c\/td\u003e\n\u003ctd\u003eup to 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurer revenue share\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital top 20 discharges\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumers price-compare\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCR sensitivity\u003c\/td\u003e\n\u003ctd\u003e95–99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pbuyers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFulgent Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Fulgent Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups—fully formatted, professionally written, and ready for download and use the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747141661049,"sku":"fulgentgenetics-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fulgentgenetics-five-forces-analysis.png?v=1772195337","url":"https:\/\/growthsharematrix.com\/products\/fulgentgenetics-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}